Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial
Bayer's NUBEQA improved four-year metastasis-free survival to 95% in high-risk prostate cancer. Overall survival evidence remains immature.
Pharma & Biotech
Pharma & Biotech
Tenax heart failure drug fails Phase 3 test despite 49% drop in cardiac stress biomarker
TNX-103 misses its Phase 3 LEVEL endpoints as Tenax shares collapse. See why a 26.3-meter subgroup benefit could keep the program alive.
Pharma & Biotech
Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply
Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.
Pharma & Biotech
NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals
Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.
Pharma & Biotech
What Orion Corporation’s FDA orphan designation for ODM-212 means for mesothelioma treatment innovation
Discover how Orion Corporation’s ODM-212 orphan drug status could reshape mesothelioma treatment and drive innovation in Hippo pathway targeting.